From: Prophylactic and therapeutic DNA vaccines against Chagas disease
Vector | Model | Immune Response | Survival (%) | Recombinant antigen | Reference |
---|---|---|---|---|---|
pCMVI.UBF3/2 | C57BL/6 | Th1 | 30-60 | ASP-1, ASP-2 and TSA-1 | 29 |
pcDNA3 | BALB/c | Th1 | 100 | Clone 9 (ASP-2) | 30 |
pCMV | BALB/c | ND | 25-100 | TSSA | 31 |
C57BL/6 | |||||
pcDNA3 | BALB/c | Th1 | ND | catalytic domain of a trans-sialidase | 32 |
pcDNA3.1 | C57BL/6 | Th1 | ND | TcG1, TcG2 and TcG4 | 33 |
pBK-CMV | BALB/c | Th1/Th2 | 92 | TcSP | 35 |
pBK-CMV | BALB/c | Th1 | 75 | TcSSP4 | 36 |
pBK-CMV | Beagle dogs | Th1 | 100 | TcSP, TcSSP4 | 37 |
pSCREEN | BALB/c | Th1 | ND | Cruzipain | 40 |
pcDNA3 | C3H/HeN | Th1 | 100 | Cruzipain | 41 |
pCMV | C57BL/6J | Th1 | 80 | LYT1 | 42 |
Vaccinia Virus | BALB/c | Th1 | 25-50 | ANYNFTLV epitope | 43 |
pcDNA3.1 | BALB/c | ND | 70 | Tc13 | 44 |
pCMV4 | BALB/c and C57BL/6 transgenic mice | Th1 | 75 | PFR2 and PFR3 | 45 |
pcDNA3.1 | Holtzman rats | Th1/Th2 | ND | CCL4/MIP-1 beta chemokine | 46 |